Retatrutide has earned a reputation as the most powerful weight-loss drug yet reported — a reputation built almost entirely on a single number. In its Phase 2 obesity trial, the highest dose produced a mean weight reduction of roughly 24.2%, edging past tirzepatide's celebrated 20.9%.[1][2] On paper, that looks like a clear winner. In practice, the comparison is far less settled than the headline suggests, and getting the caveats right matters more here than almost anywhere else in the GLP-1 conversation.
Why retatrutide might be more powerful: a third receptor
Tirzepatide is a dual agonist, activating the GLP-1 and GIP receptors. Retatrutide adds a third target: the glucagon receptor. Glucagon-receptor agonism is thought to increase energy expenditure and affect hepatic fat handling, on top of the appetite-suppressing and insulin-related effects of the GLP-1 and GIP arms. The mechanistic logic is genuinely appealing — a third lever that the dual agonist does not pull. But mechanism predicts direction, not magnitude, and it has never on its own settled a clinical question.
The numbers everyone compares — and why they don't line up
In the retatrutide Phase 2 obesity trial, 338 adults were randomized to retatrutide (up to 12 mg) or placebo for 48 weeks. The 12 mg group lost a least-squares mean of about 24.2% of body weight, versus 2.1% with placebo.[1] In SURMOUNT-1, tirzepatide at 15 mg produced a mean reduction of about 20.9% over 72 weeks, versus 3.1% with placebo.[2] The retatrutide figure is numerically larger — but it comes from a shorter trial, a smaller and separate population, and an earlier phase of development.
- Retatrutide 12 mg24.2%
Phase 2 · 48 wk · investigational
- Tirzepatide 15 mg20.9%
SURMOUNT-1 · 72 wk · FDA-approved
The bar chart highlights tirzepatide not because it lost the numbers race, but because it is the one drug a patient can actually be prescribed today — with a longer trial behind the figure. Reading the two bars as a contest would be a mistake: they answer different questions asked of different people over different timeframes.
The comparison at a glance
| Retatrutide | Tirzepatide | |
|---|---|---|
| Mechanism | GIP + GLP-1 + glucagon (triple agonist) | GIP + GLP-1 (dual agonist) |
| Regulatory status | Investigational — not approved | FDA-approved (Zepbound / Mounjaro) |
| Best reported weight loss | ≈ 24.2% (12 mg) | ≈ 20.9% (15 mg) |
| Trial phase & length | Phase 2 · 48 weeks · n=338 | Phase 3 (SURMOUNT-1) · 72 weeks |
| Available now? | No | Yes |
The single fact that settles the “which is better” debate
There is no head-to-head trial. No study has randomized patients to retatrutide versus tirzepatide. Every side-by-side figure you will see — including the one in this article — is a cross-trial estimate, the weakest form of comparison. Cross-trial numbers can be distorted by differences in baseline weight, trial length, dropout handling, and study population. They are suggestive, never decisive.
For context, retatrutide also posted strong results in a separate Phase 2 trial in people with type 2 diabetes, reinforcing that the triple-agonist mechanism is active across populations.[3] But that, too, is early-phase data — encouraging, not confirmatory.
The honest bottom line
On the narrow question of peak reported weight loss, retatrutide's number is the largest yet published — first in Phase 2, and now higher still in Phase 3 topline results — and its triple-agonist mechanism gives a plausible reason why. But “largest number” is not “better drug.” Tirzepatide is approved, available, and supported by a longer pivotal trial; retatrutide is still investigational, still not FDA-submitted, and never tested against tirzepatide directly. If retatrutide reaches the market with its current efficacy intact, this comparison will become a real clinical question. Until then, the only fully proven, prescribable option here is tirzepatide.
For the mechanism behind retatrutide's third receptor, see our retatrutide Phase 2 evidence review. For how tirzepatide stacks up against the other approved GLP-1 drug, see tirzepatide vs semaglutide and Zepbound vs Wegovy. You can also line the drugs up side by side with our GLP-1 comparison tool.